Yüklüyor......
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV‑1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation
We previously reported a milestone in the optimization of NBD-11021, an HIV-1 gp120 antagonist, by developing a new and novel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV-1(HXB2), with a half maximal inhibitory concentration of 89 nM. However, cytotoxicity remained high, a...
Kaydedildi:
| Yayımlandı: | J Med Chem |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7703574/ https://ncbi.nlm.nih.gov/pubmed/32031803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.9b02149 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|